Literature DB >> 23676786

Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye.

Shizuka Koh1, Yasushi Inoue, Toshiki Sugmimoto, Naoyuki Maeda, Kohji Nishida.   

Abstract

PURPOSE: To determine the effect of rebamipide ophthalmic suspension on optical quality in patients with dry eye with short break-up time (BUT) of the tear film.
METHODS: Twenty-six eyes of 16 patients with the short BUT type of dry eye were enrolled and treated with 2% rebamipide ophthalmic suspension. At baseline and at 2 and 4 weeks after initiating the treatment, the serial corneal higher-order aberrations (HOAs), BUT, fluorescein staining, and Schirmer test were measured. Patients were asked to complete questionnaires about the changes in dry eye-related ocular symptoms after the treatment.
RESULTS: Before the treatment, the pattern of postblink corneal HOAs for 10 seconds showed a sawtooth pattern, with a marked upward curve that increased after blinking. Treatment with rebamipide for 4 weeks significantly (P < 0.05) improved the postblink corneal HOAs and stabilized the pattern of the corneal HOAs. Significant increases in the tear film BUT were seen 2 and 4 weeks after the treatment (P < 0.001 for both comparisons).
CONCLUSIONS: Rebamipide administered to treat the short BUT type of dry eye significantly improved optical quality because of the improvement in tear stability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23676786     DOI: 10.1097/ICO.0b013e318294f97e

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  15 in total

1.  Histological observation of goblet cells following topical rebamipide treatment of the human ocular surface: A case report.

Authors:  Satoru Kase; Toshiya Shinohara; Manabu Kase
Journal:  Exp Ther Med       Date:  2014-12-05       Impact factor: 2.447

2.  Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.

Authors:  Yoshihiko Isshiki; Hiroto Ishikawa; Osamu Mimura
Journal:  Jpn J Ophthalmol       Date:  2016-08-08       Impact factor: 2.447

3.  Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study.

Authors:  J Ye; Y-F Xu; L-X Lou; K Jin; Q Miao; X Ye; Y Xi
Journal:  Eye (Lond)       Date:  2015-05-08       Impact factor: 3.775

4.  Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.

Authors:  Kaori Ueda; Wataru Matsumiya; Keiko Otsuka; Yoshifumi Maeda; Takayuki Nagai; Makoto Nakamura
Journal:  BMC Ophthalmol       Date:  2015-06-06       Impact factor: 2.209

5.  Topical rebamipide improves lid wiper epitheliopathy.

Authors:  Hirotaka Itakura; Tomoyuki Kashima; Mariko Itakura; Hideo Akiyama; Shoji Kishi
Journal:  Clin Ophthalmol       Date:  2013-10-31

6.  Changes of Corneal Wavefront Aberrations in Dry Eye Patients after Treatment with Artificial Lubricant Drops.

Authors:  Ning Lu; Fangyu Lin; Zhu Huang; Qin He; Wei Han
Journal:  J Ophthalmol       Date:  2016-03-14       Impact factor: 1.909

7.  Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?

Authors:  Wendy R Kam; Yang Liu; Juan Ding; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

8.  A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers.

Authors:  Jun Shimazaki; Den Seika; Masamichi Saga; Kazumi Fukagawa; Miki Sakata; Miki Iwasaki; Takashi Okano
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

Review 9.  Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.

Authors:  Tomoyuki Kashima; Hirotaka Itakura; Hideo Akiyama; Shoji Kishi
Journal:  Clin Ophthalmol       Date:  2014-05-30

10.  The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline.

Authors:  Laura A Vickers; Preeya K Gupta
Journal:  Ophthalmol Ther       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.